Ivermectin, fluvoxamine and metformin not effective at preventing severe COVID-19

Embargoed until: Publicly released: 2022-08-18 07:00

International

Photo by CDC on Unsplash

Ivermectin, fluvoxamine and metformin don't appear to significantly reduce the severe outcomes of COVID-19; hypoxemia, emergency department visits, hospitalisation and death, according to international research. The team tested the repurposed drugs as early intervention treatments in a double-blind, randomised placebo-controlled trial across 1323 at-risk COVID-19 patients. They say none of the drugs had a significant effect on the four severe COVID-19 outcomes combined. While metformin showed a potential association with lower hospitalisations, ER visits, and death, it was not strong enough to make a conclusion without more research, the team says.

Media release

From:

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page The URL will go live after the embargo ends

Journal/
conference: New England Journal of Medicine

Research:Paper

Organisation/s: University of Minnesota, USA

Funder: Funded by the Parsemus Foundation and others; COVID-OUT ClinicalTrials.gov number, NCT04510194

Media Contact/s

Contact details are only visible to registered journalists.